Effectiveness of the 2025–2026 trivalent influenza vaccine against laboratory-confirmed influenza among older adults in Eastern China: A test-negative case–control study
- 1Department of Immunity, Shengzhou Center for Disease Control and Prevention, Shengzhou, Zhejiang, China
Abstract
Evidence on the real-world effectiveness of seasonal influenza vaccination among older adults in China remains limited and varies by season and circulating virus. We used a test-negative case–control design to estimate the effectiveness of the 2025–2026 trivalent influenza vaccine against medically attended, laboratory-confirmed influenza among adults aged ≥60 years attending two sentinel hospitals in Shengzhou, Zhejiang Province. Participants vaccinated ≥14 days before symptom onset were considered vaccinated; those vaccinated 0–13 days before onset were excluded from the primary analysis. Vaccine effectiveness (VE) was calculated as (1 − adjusted odds ratio) × 100% using multivariable logistic regression. Among 532 participants in the primary analysis, 156 were influenza-positive cases and 376 were test-negative controls. Effective current-season vaccination was recorded in 32.7% of cases and 48.4% of controls. Adjusted VE against any influenza was 46% (95% confidence interval [CI], 18–64). Type-specific VE was 42% (95% CI, 8–63) against influenza A and 60% (95% CI, 14–81) against influenza B. Subtype-specific estimates were less precise, and interaction analyses did not identify differences by age group or chronic-disease status. The overall estimate remained stable across diagnostic restrictions and alternative model specifications. The 2025–2026 trivalent influenza vaccine was associated with moderate protection against medically attended influenza in older adults under routine program conditions, supporting continued seasonal vaccination and multi-season surveillance.
Related
- 2025/26 subclade-specific influenza A and B vaccine effectiveness estimates and discordant laboratory-based indicators of vaccine match or mismatch
- Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program
- Immunogenicity and safety of trivalent inactivated influenza vaccine in adults living with HIV compared with HIV-uninfected adults: a study from China
- Testing the 40% to 60% Influenza Vaccine Effectiveness Heuristic
- An LLM enabled real-time estimation of seasonal influenza vaccine effectiveness from social media data
BibTeX
@article{shen2026effectiveness,
title = {{Effectiveness of the 2025–2026 trivalent influenza vaccine against laboratory-confirmed influenza among older adults in Eastern China: A test-negative case–control study}},
author = {Yugang Shen and Ling Zhang and Qianmei Liu and Xiaoyang Ou and Jiawen Qian and Libo Ren},
journal = {Human Vaccines \& Immunotherapeutics},
year = {2026},
month = nov,
doi = {10.1080/21645515.2026.2759393},
url = {https://doi.org/10.1080/21645515.2026.2759393},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Effectiveness of the 2025–2026 trivalent influenza vaccine against laboratory-confirmed influenza among older adults in Eastern China: A test-negative case–control study
AU - Yugang Shen
AU - Ling Zhang
AU - Qianmei Liu
AU - Xiaoyang Ou
AU - Jiawen Qian
AU - Libo Ren
PY - 2026
DA - 2026/11/08
JO - Human Vaccines & Immunotherapeutics
DO - 10.1080/21645515.2026.2759393
UR - https://doi.org/10.1080/21645515.2026.2759393
AB - Evidence on the real-world effectiveness of seasonal influenza vaccination among older adults in China remains limited and varies by season and circulating virus. We used a test-negative case–control design to estimate the effectiveness of the 2025–2026 trivalent influenza vaccine against medically attended, laboratory-confirmed influenza among adults aged ≥60 years attending two sentinel hospitals in Shengzhou, Zhejiang Province. Participants vaccinated ≥14 days before symptom onset were considered vaccinated; those vaccinated 0–13 days before onset were excluded from the primary analysis. Vaccine effectiveness (VE) was calculated as (1 − adjusted odds ratio) × 100% using multivariable logistic regression. Among 532 participants in the primary analysis, 156 were influenza-positive cases and 376 were test-negative controls. Effective current-season vaccination was recorded in 32.7% of cases and 48.4% of controls. Adjusted VE against any influenza was 46% (95% confidence interval [CI], 18–64). Type-specific VE was 42% (95% CI, 8–63) against influenza A and 60% (95% CI, 14–81) against influenza B. Subtype-specific estimates were less precise, and interaction analyses did not identify differences by age group or chronic-disease status. The overall estimate remained stable across diagnostic restrictions and alternative model specifications. The 2025–2026 trivalent influenza vaccine was associated with moderate protection against medically attended influenza in older adults under routine program conditions, supporting continued seasonal vaccination and multi-season surveillance.
SN - 2164-5515
SN - 2164-554X
ER -